Centofanti Kevin 4
4 · GENEREX BIOTECHNOLOGY CORP · Filed Oct 15, 2018
Insider Transaction Report
Form 4
Centofanti Kevin
Director
Transactions
- Award
Stock Option (right to buy)
2018-10-03+1,000→ 1,000 totalExercise: $2.23Exp: 2028-10-03→ Common Stock (1,000 underlying)
Footnotes (1)
- [F1]The option vests in three equal annual installments beginning on October 3, 2018.